Vaxcyte, Inc.
PCVX
$54.58
-$1.63-2.90%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 129.37M | 125.70M | 116.24M | 105.68M | 92.90M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 923.68M | 811.56M | 709.11M | 635.87M | 569.55M |
| Operating Income | -923.68M | -811.56M | -709.11M | -635.87M | -569.55M |
| Income Before Tax | -766.63M | -657.20M | -547.50M | -509.63M | -463.93M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -766.63 | -657.20 | -547.50 | -509.63 | -463.93 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -766.63M | -657.20M | -547.50M | -509.63M | -463.93M |
| EBIT | -923.68M | -811.56M | -709.11M | -635.87M | -569.55M |
| EBITDA | -907.28M | -799.80M | -698.62M | -626.91M | -562.54M |
| EPS Basic | -5.63 | -4.84 | -4.11 | -3.98 | -3.80 |
| Normalized Basic EPS | -3.52 | -3.02 | -2.57 | -2.49 | -2.37 |
| EPS Diluted | -5.63 | -4.84 | -4.11 | -3.98 | -3.80 |
| Normalized Diluted EPS | -3.52 | -3.02 | -2.57 | -2.49 | -2.37 |
| Average Basic Shares Outstanding | 544.35M | 543.12M | 530.62M | 511.84M | 487.84M |
| Average Diluted Shares Outstanding | 544.35M | 543.12M | 530.62M | 511.84M | 487.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |